Topic

Zanzalintinib (XL092) [investigational]

A collection of 39 issues

If Zanzalintinib (XL092) Isn't Approved by UnitedHealthcare in New Jersey: Formulary Alternatives & Exception Paths

Answer Box: Getting Zanzalintinib (XL092) Coverage in New Jersey Zanzalintinib (XL092) is investigational and typically denied by UnitedHealthcare outside clinical trials. Your fastest path: (1) Check trial eligibility at ClinicalTrials.gov—patients with ≤2 prior TKIs may qualify; (2) If ineligible, request medical exception through OptumRx for compassionate use with

Getting Zanzalintinib (XL092) Covered by Humana in New Jersey: Clinical Trial Access and Compassionate Use Guide

Quick Answer: Your Path to Zanzalintinib Access in New Jersey Zanzalintinib (XL092) is investigational and not FDA-approved, so Humana won't cover the drug itself—but you have two main paths: clinical trials (free drug) or compassionate use (free drug, insurance covers monitoring). In New Jersey, if Humana denies

Work With Your Doctor to Get Zanzalintinib (XL092) Covered by Aetna in New York: Provider Partnership Guide

Answer Box: Your Partnership Path to Coverage Zanzalintinib (XL092) requires close collaboration with your oncologist since it's investigational and only available through Exelixis's compassionate use program or clinical trials. In New York, your fastest path involves: (1) Your doctor submitting FDA Form 3926 for expanded access,

Getting Zanzalintinib (XL092) Covered by UnitedHealthcare in Pennsylvania: Clinical Trial Access and Compassionate Use Appeals Guide

Answer Box: Your Fastest Path to Zanzalintinib Coverage Getting Zanzalintinib (XL092) covered by UnitedHealthcare in Pennsylvania requires clinical trial enrollment or compassionate use approval, since this investigational TKI has no FDA approval. Your three options: (1) Enroll in an active STELLAR program trial where UnitedHealthcare covers routine monitoring costs, (2)

Getting Zanzalintinib (XL092) Covered by Cigna in Michigan: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Zanzalintinib (XL092) Covered by Cigna in Michigan Zanzalintinib (XL092) is investigational and typically not covered by Cigna outside clinical trials or compassionate use programs. Your fastest path: 1) Check if you qualify for an Exelixis expanded access program, 2) Have your oncologist submit a detailed prior authorization

Getting Zanzalintinib (XL092) [investigational] Covered by Humana in New York: Clinical Trial Access and Compassionate Use Pathways

Answer Box: Your Fastest Path to Zanzalintinib (XL092) Access Zanzalintinib is investigational—Humana won't cover it as a standard drug. Your three pathways: 1) Clinical trials (search ClinicalTrials.gov for "XL092" or "zanzalintinib"), 2) Exelixis Expanded Access Program (free drug, insurance covers routine care)

Getting Zanzalintinib (XL092) Covered by Humana in Illinois: Clinical Trial Access and Compassionate Use Appeals

Quick Answer: Zanzalintinib (XL092) is an investigational cancer drug not yet FDA-approved, so Humana typically won't cover it outside clinical trials. Your fastest path: 1) Ask your oncologist to check active trials at ClinicalTrials.gov, 2) If trial-ineligible, request compassionate use through Exelixis, 3) Submit Humana formulary exception

The Requirements Checklist to Get Zanzalintinib (XL092) Covered by Humana in Georgia: Clinical Trials, Appeals, and Compassionate Use Pathways

Answer Box: Getting Zanzalintinib (XL092) Coverage in Georgia Zanzalintinib (XL092) is investigational with no FDA approval, making standard Humana coverage unlikely. Your fastest path: 1) Check eligibility for active clinical trials (drug provided free), 2) Contact Exelixis Medical Affairs for compassionate use if trial-ineligible, or 3) Submit prior authorization with

The Requirements Checklist to Get Zanzalintinib (XL092) Covered by UnitedHealthcare in Georgia: Appeals, Compassionate Use, and Clinical Trial Access

Answer Box: Getting Zanzalintinib (XL092) Covered by UnitedHealthcare in Georgia Zanzalintinib (XL092) is an investigational cancer drug not FDA-approved, making UnitedHealthcare coverage unlikely outside clinical trials. Your fastest path: 1) Apply for Exelixis's Expanded Access Program (drug provided free), 2) Submit UnitedHealthcare prior authorization for routine care costs

How to Get Zanzalintinib (XL092) Covered by Humana in Virginia: Appeals Guide for Investigational Cancer Treatment

Answer Box: Getting Zanzalintinib (XL092) Coverage from Humana in Virginia Zanzalintinib (XL092) is investigational and typically denied by Humana as "not covered outside clinical trials." However, you have three main pathways: 1) Request a formulary exception with strong medical necessity documentation, 2) Apply for Exelixis' compassionate use